Clougher, Derek
Forte, Maria Florencia
Mezquida Mateos, Gisela
Sánchez Torres, Ana M.
Serra Navarro, Maria
Penadés Rubio, Rafael
Lobo, Antonio
González-Pinto, Ana
Panadero Gómez, Rocío
Roldán, Alexandra
Vieta i Pascual, Eduard, 1963-
Serna, Elena de la, 1978-
Trabsa, Amira
Martínez-Arán, Anabel, 1971-
Torrent Font, Carla
Tortorella, Alfonso
Menculini, Giulia
Ramos-Quiroga, Josep Antoni
Cuesta, Manuel J.
Bernardo Arroyo, Miquel
Amoretti Guadall, Silvia
PEPs Group
2025-10-09T13:03:52Z
2025-10-09T13:03:52Z
2024-08-01
2025-10-09T13:03:53Z
Emotional intelligence (EI) and neurocognition (NC) impairments are common in first-episode psychosis (FEP), yet their evolution over time remains unclear. This study identified patient profiles in EI and NC performance in FEP. 98 adult FEP patients and 128 healthy controls (HCs) were tested on clinical, functional, EI, and NC variables at baseline and two-year follow-up (FUP). A repeated-measures ANOVA compared the effects of group (patients and HCs) and time on EI. Significant EI improvements were observed in both groups. Four groups were created based on NC and EI performance at baseline and FUP in patients: impairment in NC and EI, impairment in NC only, impairment in EI only, and no impairment. At FUP, patients impaired in NC and EI showed less cognitive reserve (CR), greater negative and positive symptoms, and poorer functional outcomes. At FUP, three group trajectories were identified: (I) maintain dual impairment (II) maintain no impairment or improve, (III) maintain sole impairment or worsen. The maintain dual impairment group had the lowest levels of CR. EI and NC impairments progress differently in FEP. Greater CR may protect against comorbid EI/NC impairment. Identifying these patient characteristics could contribute to the development of personalised interventions.
English
Neurociència cognitiva; Psicosi; Intel·ligència emocional; Cognitive neuroscience; Psychoses; Emotional intelligence
Elsevier B.V.
Reproducció del document publicat a: https://doi.org/10.1016/j.euroneuro.2024.05.006
European Neuropsychopharmacology, 2024, vol. 85, p. 66-77
https://doi.org/10.1016/j.euroneuro.2024.05.006
cc-by (c) Clougher, Derek et al., 2024
http://creativecommons.org/licenses/by/4.0/